Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

The trial for the motorcyclist charged with hitting and killing a 13-year-old boy during an alleged street race in St. Petersburg is underway. Experts used a mannequin on Thursday to simulate what a ...